UNH researchers discover new inhibitor drug combination for rare form of cancer
(University of New Hampshire) Researchers at the University of New Hampshire took the novel approach of targeting specific cell proteins that control DNA information using inhibitors, or drugs, that were effective in reducing the growth of the Waldenstr ö m macroglobulinemia cancer cells and when combined with a third drug were even more successful in killing the WM cancer cells which could lead to more treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2021 Category: Cancer & Oncology Source Type: news
New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with IMBRUVICA® remai...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discont...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial
The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA Source Type: news
Zanubrutinib Appears to be Safe, Effective for Waldenstr öm Macroglobulinemia
According to the largest phase III trial examining BTK inhibitors for patients with Waldenstr öm macroglobulinemia, zanubrutinib appears to be associated with higher complete response or very good partial response, as well as clinically meaningful advantages in safety and tolerability compared to ibrutinib. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news
FDA Grants Fast Track Designation for CLR 131 in LPL/WM
The FDA granted fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom ’s macroglobulinemia in patients having received 2 prior treatment regimens or more. (Source: CancerNetwork)
Source: CancerNetwork - May 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s milestone mar...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
To My Husband in Quarantine on Day 18
Incurable cancer and chemo have devastated my immune system. My husband ’s strict isolation is an act of Covid-19 contagion chivalry. (Source: NYT Health)
Source: NYT Health - April 13, 2020 Category: Consumer Health News Authors: Lisa J. Wise Tags: Coronavirus (2019-nCoV) Quarantines Marriages Fever Waldenstrom ' s Macroglobulinemia Loneliness Lymphoma Source Type: news
Lymphoma Control Better Goal Than Remission Lymphoma Control Better Goal Than Remission
Drugs used to treat lymphoplasmacytic lymphoma can have adverse effects, so lowering therapeutic targets might help, delegates heard at the International Waldenstrom ' s Macroglobulinemia Forum.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New Lymphoma Drugs Build on BTK Inhibitor Success New Lymphoma Drugs Build on BTK Inhibitor Success
Life expectancy for patients with Waldenstrom ' s macroglobulinemia has improved considerably in the past decade, and new treatments on the horizon could mean that trend continues.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 31, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Patients With Rare Lymphoma Describe Divergent Experiences Patients With Rare Lymphoma Describe Divergent Experiences
Some people are treated aggressively while others watch and wait until symptoms appear; three will describe their experiences at the upcoming Waldenstrom ' s Macroglobulinemia forum.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Model Predicts Progression Risk for Rare Type of Lymphoma
Model can improve monitoring of patients with asymptomatic Waldenstr ö m macroglobulinemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2019 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news
Model Predicts Progression Risk for Rare Type of Lymphoma
FRIDAY, May 3, 2019 -- A publicly available model can identify patients with asymptomatic Waldenstr öm macroglobulinemia (AWM) at high risk for progression, according to a study published online April 16 in the Journal of Clinical Oncology.
Mark... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2019 Category: Pharmaceuticals Source Type: news
Researchers devise a progression risk-based classification for patients with AWM
(Dana-Farber Cancer Institute) Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenstr ö m macroglobulinemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 23, 2019 Category: International Medicine & Public Health Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - August 27, 2018 Category: Pharmaceuticals Source Type: news
